Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for BCRX

Stock NameBioCryst Pharmaceuticals Inc
TickerBCRX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS09058V1035
LEI549300Z0INP1Z5NP6J59

Show aggregate BCRX holdings

News associated with BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price […] - 2025-09-05 04:29:03
Headlands Technologies LLC Buys New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,219 shares of the biotechnology company’s stock, valued at approximately $32,000. A number of […] - 2025-08-14 04:45:23
New Age Alpha Advisors LLC Takes $62,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
New Age Alpha Advisors LLC acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,235 shares of the biotechnology company’s stock, valued at approximately $62,000. A number of other institutional […] - 2025-08-12 05:00:48
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year […] - 2025-08-11 02:28:49
XTX Topco Ltd Acquires 66,320 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
XTX Topco Ltd increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 314.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,389 shares of the biotechnology company’s stock after purchasing an additional 66,320 shares during the […] - 2025-08-06 05:57:13
Mackenzie Financial Corp Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Mackenzie Financial Corp grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 37.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,258 shares of the biotechnology company’s stock after purchasing an additional 31,596 shares during the period. […] - 2025-08-06 05:18:53
Universal Beteiligungs und Servicegesellschaft mbH Makes New $125,000 Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 16,704 shares of the biotechnology company’s stock, valued at approximately $125,000. Other hedge funds have also modified their […] - 2025-08-06 04:28:49
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Strong Earnings
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) shares gapped up before the market opened on Monday following a stronger than expected earnings report. The stock had previously closed at $7.95, but opened at $9.14. BioCryst Pharmaceuticals shares last traded at $8.32, with a volume of 2,333,940 shares traded. The biotechnology company reported $0.15 earnings […] - 2025-08-06 02:13:11
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Cerity Partners LLC
Cerity Partners LLC boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 203.6% in the 1st quarter, Holdings Channel reports. The firm owned 36,410 shares of the biotechnology company’s stock after purchasing an additional 24,418 shares during the period. Cerity Partners LLC’s holdings in BioCryst Pharmaceuticals were worth $273,000 at the end […] - 2025-07-28 04:46:48
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Wall Street Zen
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday. A number of other research firms have also recently commented on BCRX. Needham & Company LLC restated a “buy” rating […] - 2025-07-28 02:18:50
Y Intercept Hong Kong Ltd Buys 73,242 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Y Intercept Hong Kong Ltd grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 106.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 141,865 shares of the biotechnology company’s stock after purchasing an additional 73,242 shares during the period. Y Intercept Hong Kong Ltd’s holdings in BioCryst Pharmaceuticals were worth […] - 2025-07-25 06:52:53
Bank of America Raises BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $15.00
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price raised by equities research analysts at Bank of America from $13.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s target price indicates a potential upside of […] - 2025-07-03 04:38:51
Wedbush Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its price target raised by research analysts at Wedbush from $16.00 to $18.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s price target would indicate a potential upside of 100.00% from the company’s current price. […] - 2025-07-02 02:32:50
BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Outperform” Rating from Royal Bank Of Canada
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Royal Bank Of Canada in a report released on Monday,Benzinga reports. They currently have a $13.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 44.44% from the […] - 2025-07-02 02:32:47
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 5.2% during the first quarter, HoldingsChannel reports. The fund owned 43,496 shares of the biotechnology company’s stock after acquiring an additional 2,146 shares during the quarter. SG Americas Securities LLC’s holdings in BioCryst Pharmaceuticals were worth $326,000 […] - 2025-06-26 04:58:58
Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $16.56
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year […] - 2025-06-25 02:44:54
Peek Under The Hood: FHLC Has 21% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-20 08:15:40
Millennium Management LLC Sells 634,095 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Millennium Management LLC cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 44.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 790,105 shares of the biotechnology company’s stock after selling 634,095 shares during the quarter. Millennium Management LLC’s holdings […] - 2025-05-28 04:56:50
ProShare Advisors LLC Has $511,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
ProShare Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,004 shares of the biotechnology company’s stock after purchasing an additional 16,732 shares during the period. ProShare […] - 2025-05-27 05:36:51
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Man Group plc
Man Group plc increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 46.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,954 shares of the biotechnology company’s stock after purchasing an additional 28,481 shares during the period. Man Group […] - 2025-05-26 05:01:05
Wall Street Zen Upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) to “Strong-Buy”
Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a buy rating to a strong-buy rating in a research note published on Thursday. BCRX has been the subject of several other research reports. JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the […] - 2025-05-23 04:32:52
Lazard Asset Management LLC Buys 65,420 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Lazard Asset Management LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 68.1% during the fourth quarter, Holdings Channel reports. The fund owned 161,516 shares of the biotechnology company’s stock after acquiring an additional 65,420 shares during the quarter. Lazard Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $1,214,000 as […] - 2025-05-20 06:00:50
The Manufacturers Life Insurance Company Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
The Manufacturers Life Insurance Company decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 65.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 103,531 shares of the biotechnology company’s stock after selling 195,621 shares during the period. The Manufacturers Life Insurance Company’s holdings in […] - 2025-05-15 04:45:06
10,670 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Raymond James Financial Inc.
Raymond James Financial Inc. purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,670 shares of the biotechnology company’s stock, valued at approximately $80,000. Several other institutional […] - 2025-05-14 04:26:53
Mariner LLC Grows Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Mariner LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,258 shares of the biotechnology company’s stock after purchasing an additional 3,224 shares during the quarter. […] - 2025-05-09 05:08:42
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $17.00 Price Target at Needham & Company LLC
BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Wedbush assumed coverage on […] - 2025-05-09 04:26:42
Tudor Investment Corp ET AL Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Tudor Investment Corp ET AL bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 99,450 shares of the biotechnology company’s stock, valued at approximately $748,000. A number of other institutional […] - 2025-05-08 06:44:51
JPMorgan Chase & Co. Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price lifted by JPMorgan Chase & Co. from $10.00 to $13.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 28.97% […] - 2025-05-08 05:04:48
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Earnings Beat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report)’s stock price gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $8.93, but opened at $9.80. BioCryst Pharmaceuticals shares last traded at $10.03, with a volume of 5,915,215 shares changing hands. The biotechnology […] - 2025-05-07 02:20:57
Investors Buy Large Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 2,675 call options on the company. This represents an increase of approximately 174% compared to the average daily volume of 975 call options. BioCryst Pharmaceuticals Price Performance Shares of BCRX stock opened at […] - 2025-05-07 02:20:55

iShares Healthcare Innovation UCITS ETF USD (Acc) BCRX holdings

DateNumber of BCRX Shares HeldBase Market Value of BCRX SharesLocal Market Value of BCRX SharesChange in BCRX Shares HeldChange in BCRX Base ValueCurrent Price per BCRX Share HeldPrevious Price per BCRX Share Held
2025-11-11 (Tuesday)252,473USD 1,825,380BCRX holding increased by 7574USD 1,825,3800USD 7,574 USD 7.23 USD 7.2
2025-11-10 (Monday)252,473USD 1,817,806BCRX holding increased by 27772USD 1,817,8060USD 27,772 USD 7.2 USD 7.09
2025-11-07 (Friday)252,473USD 1,790,034BCRX holding increased by 15149USD 1,790,0340USD 15,149 USD 7.09 USD 7.03
2025-11-06 (Thursday)252,473USD 1,774,885BCRX holding decreased by -35346USD 1,774,8850USD -35,346 USD 7.03 USD 7.17
2025-11-05 (Wednesday)252,473USD 1,810,231BCRX holding increased by 103514USD 1,810,2310USD 103,514 USD 7.17 USD 6.76
2025-11-04 (Tuesday)252,473USD 1,706,717BCRX holding decreased by -25248USD 1,706,7170USD -25,248 USD 6.76 USD 6.86
2025-11-03 (Monday)252,473USD 1,731,965BCRX holding decreased by -116137USD 1,731,9650USD -116,137 USD 6.86 USD 7.32
2025-10-31 (Friday)252,473USD 1,848,102BCRX holding increased by 17673USD 1,848,1020USD 17,673 USD 7.32 USD 7.25
2025-10-30 (Thursday)252,473USD 1,830,429BCRX holding decreased by -15149USD 1,830,4290USD -15,149 USD 7.25 USD 7.31
2025-10-29 (Wednesday)252,473USD 1,845,578BCRX holding increased by 17673USD 1,845,5780USD 17,673 USD 7.31 USD 7.24
2025-10-28 (Tuesday)252,473USD 1,827,905BCRX holding decreased by -17673USD 1,827,9050USD -17,673 USD 7.24 USD 7.31
2025-10-27 (Monday)252,473USD 1,845,578BCRX holding increased by 27772USD 1,845,5780USD 27,772 USD 7.31 USD 7.2
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of BCRX by Blackrock for IE00BYZK4776

Show aggregate share trades of BCRX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-24SELL-2,1467.2007.340 7.326USD -15,722 8.44 Profit of 2,393 on sale
2025-09-11BUY1,0798.0708.130 8.124USD 8,766 8.58
2025-07-08SELL-1,0738.7908.920 8.907USD -9,557 8.59 Loss of -343 on sale
2025-06-24SELL-1,0789.93010.060 10.047USD -10,831 8.54 Loss of -1,620 on sale
2025-06-23SELL-1,0809.91010.040 10.027USD -10,829 8.53 Loss of -1,612 on sale
2025-06-11SELL-1,07610.61011.070 11.024USD -11,862 8.43 Loss of -2,790 on sale
2025-05-30SELL-1,07610.75010.880 10.867USD -11,693 8.26 Loss of -2,801 on sale
2025-05-21BUY1,07610.07010.290 10.268USD 11,048 8.12
2025-05-14SELL-6,4449.85010.220 10.183USD -65,619 8.05 Loss of -13,742 on sale
2025-04-30SELL-1,0738.8508.930 8.922USD -9,573 7.88 Loss of -1,123 on sale
2025-04-28SELL-1,0768.3208.490 8.473USD -9,117 7.87 Loss of -654 on sale
2025-04-25SELL-1,0738.3908.470 8.462USD -9,080 7.86 Loss of -646 on sale
2025-04-11SELL-6,5166.8206.850 6.847USD -44,615 7.89 Profit of 6,792 on sale
2025-04-08SELL-3,2406.4707.080 7.019USD -22,742 7.94 Profit of 2,970 on sale
2025-04-07BUY8,0766.7907.050 7.024USD 56,726 7.95
2025-03-31SELL-2,0827.5007.710 7.689USD -16,008 7.98 Profit of 612 on sale
2025-03-21SELL-2,0767.9808.100 8.088USD -16,791 7.99 Loss of -210 on sale
2025-03-12SELL-1,0477.7107.950 7.926USD -8,299 8.02 Profit of 98 on sale
2025-02-28SELL-1,0478.6108.660 8.655USD -9,062 8.02 Loss of -662 on sale
2025-02-25BUY1,0478.2808.440 8.424USD 8,820 8.00
2025-02-20SELL-1,0479.3909.500 9.489USD -9,935 7.95 Loss of -1,609 on sale
2025-02-19BUY2,0889.3909.480 9.471USD 19,775 7.93
2025-02-18BUY1,0449.3609.450 9.441USD 9,856 7.90
2024-12-30SELL-2,0317.5307.710 7.692USD -15,622 7.67 Loss of -47 on sale
2024-12-06SELL-1,0327.6108.160 8.105USD -8,364 7.66 Loss of -459 on sale
2024-12-04SELL-1,0327.3307.560 7.537USD -7,778 7.67 Profit of 133 on sale
2024-12-03SELL-2,0647.1907.430 7.406USD -15,286 7.68 Profit of 572 on sale
2024-11-21SELL-1,0477.4907.510 7.508USD -7,861 7.77 Profit of 279 on sale
2024-11-20SELL-1,0717.3007.510 7.489USD -8,021 7.80 Profit of 334 on sale
2024-11-19SELL-1,0687.2107.320 7.309USD -7,806 7.84 Profit of 562 on sale
2024-11-18SELL-4,1527.0607.140 7.132USD -29,612 7.88 Profit of 3,123 on sale
2024-11-12SELL-1,0387.8208.240 8.198USD -8,510 7.89 Loss of -321 on sale
2024-11-07SELL-1,0387.6707.880 7.859USD -8,158 7.91 Profit of 57 on sale
2024-11-05SELL-2,0707.0607.440 7.402USD -15,322 8.01 Profit of 1,255 on sale
2024-10-28SELL-1,0388.1508.230 8.222USD -8,534 7.93 Loss of -301 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of BCRX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19564,07678,653998,53456.5%
2025-09-18249,0465,213665,74137.4%
2025-09-17626,53501,344,62446.6%
2025-09-16416,5420849,25049.0%
2025-09-15513,6988731,366,16837.6%
2025-09-12336,3942401,653,91320.3%
2025-09-11343,166700941,86536.4%
2025-09-10481,8735,6841,056,28545.6%
2025-09-09312,2522,013901,72534.6%
2025-09-08209,98019,598510,10241.2%
2025-09-05321,72639,7601,095,98329.4%
2025-09-04145,25516,436438,74733.1%
2025-09-03582,14562,9121,717,14533.9%
2025-09-02351,305481941,30037.3%
2025-08-29191,7674,400800,58524.0%
2025-08-28420,8010745,72556.4%
2025-08-27178,4010405,14144.0%
2025-08-26253,8500558,42045.5%
2025-08-25406,1140839,31348.4%
2025-08-22192,2620573,42133.5%
2025-08-21221,2210458,55748.2%
2025-08-20131,1660427,34430.7%
2025-08-19146,8090764,93219.2%
2025-08-18305,8800716,73042.7%
2025-08-15228,075155881,32325.9%
2025-08-14525,21301,005,23552.2%
2025-08-13329,64901,231,19226.8%
2025-08-12401,2170894,02944.9%
2025-08-11365,779100823,30444.4%
2025-08-08296,1520726,74040.8%
2025-08-07449,0730844,61753.2%
2025-08-06468,0721,801877,45253.3%
2025-08-05850,49115,7761,611,41652.8%
2025-08-042,106,7296,2703,591,01458.7%
2025-08-012,016,6955,9403,035,43666.4%
2025-07-311,474,84702,430,62260.7%
2025-07-30489,268561,010,36448.4%
2025-07-29708,7416601,471,73548.2%
2025-07-28709,7091221,144,79662.0%
2025-07-25424,2090793,87253.4%
2025-07-24482,2920791,30460.9%
2025-07-23444,1140861,55151.5%
2025-07-22599,2182001,373,17143.6%
2025-07-21427,22401,231,50334.7%
2025-07-18492,01801,083,53445.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.